Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions)

重组Fc糖基化修饰抗CD20人源化单克隆抗体（百奥泰生物）

Report date: 2025/10/30 14:57:28

Base Information

Drug NameRecombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions)
Drug Alias Name重组Fc糖基化修饰抗CD20人源化单克隆抗体注射液BAT-4306F
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBio-Thera Solutions Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksWikipedia